Pharmaceutical identification

• US 9,226,874 B2
• Filed: 09/14/2010
• Issued: 01/05/2016
• Est. Priority Date: 10/31/2002
• Status: Active Grant

• Current Assignee: Purdue Pharma L.P.
• Original Assignee: Purdue Pharma L.P.
• Inventors: Siegel, Sheryl E.
• Primary Examiner(s): Hartley, Michael G
• Assistant Examiner(s): YOUNG, MICAH PAUL
• Application Number:
  US12/881,889
• Publication Number:
  US 20110217243A1
• Time in Patent Office: 1,939 Days
• Field of Search: 424/464, 424/441, 424/465, 424/474, 514/4, 436/181, 436/56, 436/106, 436/113
• US Class Current: 1/1
• CPC Class Codes: A61J 1/00 Containers specially adapted for medical or pharmaceutical purposes capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00
• CPC Class Codes: A61J 2200/60 biodegradable
• CPC Class Codes: A61J 2205/00 General identification or selection means
• CPC Class Codes: A61J 2205/20 Colour codes
• CPC Class Codes: A61J 2205/30 Printed labels
• CPC Class Codes: A61J 2205/60 using magnetic or electronic identifications, e.g. chips, RFID, electronic tags
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: B65D 2203/12 Audible, olfactory or visual signalling means B65D51/248, B65D55/028, B65D79/02 and B65D81/24 take precedence

Abstract

Disclosed are methods for marking a pharmaceutical product, container or pharmaceutical packaging system with a scent to establish the identity and/or source of the pharmaceutical.

Claims

1. A pharmaceutical formulation comprising a drug and an imparted volatile scent, wherein the scent comprises less than 100 ppm of the dosage form, provides an olfactory effect which is physiologically unperceivable by humans, is detectable by a non-human animal or an electronic olfactory measuring device, excludes perfluorocarbon tracers, and indicates when and/or where the pharmaceutical formulation was manufactured, bottled or packaged, and the pharmaceutical formulation is a tablet or a capsule.

2. The pharmaceutical formulation of claim 1, wherein the amount of the scent is detectable by the electronic olfactory measuring device.

3. The pharmaceutical formulation of claim 1, wherein the scent indicates where the pharmaceutical formulation was manufactured, bottled or packaged.

4. The pharmaceutical formulation of claim 1 comprising a coating.

5. The pharmaceutical formulation of claim 4, wherein the coating is a film coating.

6. The pharmaceutical formulation of claim 4, wherein the coating comprises the scent.

7. The pharmaceutical formulation of claim 1, wherein the scent is sequestered.

8. The pharmaceutical formulation of claim 1, wherein the scent comprises a plurality of scents.

18. The pharmaceutical formulation of claim 1, wherein the scent is selected from the group consisting of volatile oils, synthetic flavor oils, flavoring aromatics, natural flavor oils, flavoring liquid oleoresins, flower extracts, fruit extracts, and combinations thereof.

19. The pharmaceutical formulation of claim 1, wherein the scent is selected from the group consisting of aldehydes, esters and mixtures thereof.

20. The pharmaceutical formulation of claim 1, wherein the scent is selected from the group consisting of anise, apple, arnica, balm mint, banana, basil, black pine, caraway, carnation, chamomile, cherry, Chinese cedar wood, chocolate, cinnamon, coconut, coffee, cypress, dill weed, eucalyptus, fir, fleurier, florogenia, forest ground, fresh baked bread, ginger bread, green apple, green bean, green spruce, hay flower, hazel, honey, hyacinth, incense, jacilia, jasmine, juniper, keymi, lavender, leather, lemon, lilac, lotus, mandarin, mango, maracuja, marjoram, May-flower, menthol, mixed alpine herbs, mugol, northern birch, ocean breeze, orange, orchid, ozone pine, peach, pear, petunias, pine, pinewood, pink pepper, pizza, plum, rose, raspberry, rosemary, sandalwood, sea breeze, Siberian spruce, spring, spruce pine, strawberry, thyme, tobacco, tomato, valerian, vanilla, violet, waffle, wild woodberry, musk, and mixtures thereof.

21. The pharmaceutical formulation of claim 1, wherein the scent is selected from the group consisting of a fatty acid with short chains of two to six carbon atoms, ketones, aldehydes, amines, o- and p-hydoxy benzoic acids and their esters, and combinations thereof.

9. A pharmaceutical formulation comprising an opioid and an imparted volatile scent, wherein the scent comprises less than 100 ppm of the dosage form, provides an olfactory effect which is physiologically unperceivable by humans, is detectable by a non-human animal or an electronic olfactory measuring device, excludes perfluorocarbon tracers, and indicates when and/or where the pharmaceutical formulation was manufactured, bottled or packaged.

10. The pharmaceutical formulation of claim 9, wherein the amount of the scent is detectable by the electronic olfactory measuring device.

11. The pharmaceutical formulation of claim 9, wherein the scent indicates where the pharmaceutical formulation was manufactured, bottled or packaged.

12. The pharmaceutical formulation of claim 9 comprising a coating.

13. The pharmaceutical formulation of claim 12, wherein the coating is a film coating.

14. The pharmaceutical formulation of claim 12, wherein the coating comprises the scent.

15. The pharmaceutical formulation of claim 9, wherein the scent is sequestered.

16. The pharmaceutical formulation of claim 9, wherein the scent comprises a plurality of scents.

17. The pharmaceutical formulation of claim 9 which is a tablet or a capsule.

22. The pharmaceutical formulation of claim 9, wherein the scent is selected from the group consisting of volatile oils, synthetic flavor oils, flavoring aromatics, natural flavor oils, flavoring liquid oleoresins, flower extracts, fruit extracts, and combinations thereof.

23. The pharmaceutical formulation of claim 9, wherein the scent is selected from the group consisting of aldehydes, esters and mixtures thereof.

24. The pharmaceutical formulation of claim 9, wherein the scent is selected from the group consisting of anise, apple, arnica, balm mint, banana, basil, black pine, caraway, carnation, chamomile, cherry, Chinese cedar wood, chocolate, cinnamon, coconut, coffee, cypress, dill weed, eucalyptus, fir, fleurier, florogenia, forest ground, fresh baked bread, ginger bread, green apple, green bean, green spruce, hay flower, hazel, honey, hyacinth, incense, jacilia, jasmine, juniper, keymi, lavender, leather, lemon, lilac, lotus, mandarin, mango, maracuja, marjoram, May-flower, menthol, mixed alpine herbs, mugol, northern birch, ocean breeze, orange, orchid, ozone pine, peach, pear, petunias, pine, pinewood, pink pepper, pizza, plum, rose, raspberry, rosemary, sandalwood, sea breeze, Siberian spruce, spring, spruce pine, strawberry, thyme, tobacco, tomato, valerian, vanilla, violet, waffle, wild woodberry, musk, and mixtures thereof.

25. The pharmaceutical formulation of claim 9, wherein the scent is selected from the group consisting of a fatty acid with short chains of two to six carbon atoms, ketones, aldehydes, amines, o- and p-hydoxy benzoic acids and their esters, and combinations thereof.